{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T12:42:56Z","timestamp":1773492176515,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Servier Laboratories (Aust) Pty Ltd"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.hlc.2018.01.011","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T15:36:00Z","timestamp":1518104160000},"page":"414-422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cost-Effectiveness of Ivabradine in the Treatment of Chronic Heart Failure"],"prefix":"10.1016","volume":"28","author":[{"given":"Michael A.","family":"Adena","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Hamann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew P.","family":"Sindone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2018.01.011_bib0005","unstructured":"Australian Institute of Health and Welfare (AIHW). Heart, stroke and vascular diseases\u2014Australian facts 2004. AIHW Cat. No. CVD 27. Canberra: AIHW and National Heart Foundation of Australia (Cardiovascular Disease Series No. 22). 2004."},{"issue":"3","key":"10.1016\/j.hlc.2018.01.011_bib0010","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.hlc.2004.06.007","article-title":"Uncovering a hidden epidemic: a study of the current burden of heart failure in Australia","volume":"13","author":"Clark","year":"2004","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.hlc.2018.01.011_bib0015","unstructured":"National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand (Chronic Heart Failure Guidelines Expert Writing Panel). Guidelines for the prevention, detection and management of chronic heart failure in Australia. Updated October 2011."},{"issue":"9744","key":"10.1016\/j.hlc.2018.01.011_bib0020","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2018.01.011_bib0025","series-title":"NICE clinical guideline 108. Chronic Heart Failure Management of chronic heart failure in adults in primary and secondary care","year":"2010"},{"issue":"27","key":"10.1016\/j.hlc.2018.01.011_bib0030","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"377","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2018.01.011_bib0035","unstructured":"CORALAN Product Information. 12 June 2015 [Cited 19 October 2015]."},{"issue":"5","key":"10.1016\/j.hlc.2018.01.011_bib0040","doi-asserted-by":"crossref","first-page":"334","DOI":"10.5694\/mja12.10993","article-title":"Management of heart failure","volume":"199","author":"Krum","year":"2013","journal-title":"Med J Aust"},{"key":"10.1016\/j.hlc.2018.01.011_bib0045","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.hlc.2013.05.208","article-title":"Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate \u226577 bpm: subgroup analysis of SHIFT","volume":"22","author":"Krum","year":"2013","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.hlc.2018.01.011_bib0050","unstructured":"National Institute for Health and Care Excellence. Ivabradine for treating chronic heart failure. NICE technology appraisal guidance [TA267]. November 2012."},{"key":"10.1016\/j.hlc.2018.01.011_bib0055","series-title":"Ivabradine for the treatment of chronic heart failure: a single technology appraisal","author":"Edwards","year":"2012"},{"issue":"13","key":"10.1016\/j.hlc.2018.01.011_bib0060","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1136\/heartjnl-2013-304598","article-title":"The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective","volume":"100","author":"Griffiths","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.hlc.2018.01.011_bib0065","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1186\/s12913-014-0631-0","article-title":"Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece","volume":"14","author":"Kourlaba","year":"2014","journal-title":"BMC Health Serv Res"},{"issue":"11","key":"10.1016\/j.hlc.2018.01.011_bib0070","first-page":"626","article-title":"Cost-effectiveness and budget impact of ivabradine in heart failure therapy","volume":"15","author":"Polistena","year":"2014","journal-title":"G Ital Cardiol (Rome)"},{"key":"10.1016\/j.hlc.2018.01.011_bib0075","unstructured":"Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. Version 4.4. Australian Government Department of Health and Aging. www.pbs.gov.au\/info\/news\/2014\/01\/pbac-guidelines [accessed 09 February 2018]."},{"issue":"3","key":"10.1016\/j.hlc.2018.01.011_bib0080","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/0272989X08327494","article-title":"Long-term cost-effectiveness of disease management in systolic heart failure","volume":"29","author":"Miller","year":"2009","journal-title":"Med Decis Mak"},{"issue":"4","key":"10.1016\/j.hlc.2018.01.011_bib0085","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ahj.2005.06.007","article-title":"Prophylactic pacemaker use to allow \u03b2-blocker therapy in patients with chronic heart failure with bradycardia","volume":"151","author":"Stecker","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.hlc.2018.01.011_bib0090","unstructured":"Australian Government Actuary. Australian life tables 2010\u201312. http:\/\/www.aga.gov.au\/publications\/life_table_2010-12\/default.asp [accessed 09 February 2018]."},{"key":"10.1016\/j.hlc.2018.01.011_bib0095","unstructured":"Round 13 Cost Report, Public Sector Estimated Cost Weights Round 13 AR-DRG v5.2. http:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/Round_13-cost-reports."},{"issue":"11","key":"10.1016\/j.hlc.2018.01.011_bib0100","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med care"},{"issue":"5","key":"10.1016\/j.hlc.2018.01.011_bib0105","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1177\/0272989X08315247","article-title":"The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994\u20132004","volume":"28","author":"Harris","year":"2008","journal-title":"Med Decis Mak"},{"issue":"7","key":"10.1016\/j.hlc.2018.01.011_bib0110","doi-asserted-by":"crossref","first-page":"A416","DOI":"10.1016\/S1098-3015(11)72730-9","article-title":"PHP66 an assessment of the variation in accepted ICERS by disease type: results from four HTAs","volume":"13","author":"Ternouth","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.hlc.2018.01.011_bib0115","unstructured":"March 2013 PBAC Outcomes \u2013 Positive Recommendations, http:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/pbac-outcomes\/2013-03\/positive-recommendations [accessed 09 February 2018]."},{"key":"10.1016\/j.hlc.2018.01.011_bib0120","unstructured":"Australian Government Department of Health. Public Summary Document for Eplerenone, film coated tablets, 25 mg, 50 mg, Inspra(R), July 2005, http:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2005-07\/eplerenone [accessed 09 February 2018]."},{"key":"10.1016\/j.hlc.2018.01.011_bib0125","series-title":"Cardiac resynchronisation therapy for severe heart failure","author":"Australian Government Department of Health","year":"2006"},{"key":"10.1016\/j.hlc.2018.01.011_bib0130","series-title":"Assessment Report 32","article-title":"Implantable cardioverter defibrillators for prevention of sudden cardiac death","author":"Australian Government Department of Health","year":"2006"},{"key":"10.1016\/j.hlc.2018.01.011_bib0135","unstructured":"Australian Government. Public Summary Document. Application 1223 \u2013 Insertion, replacement or removal of a cardiac resynchronisation therapy device capable of defibrillation (CRT-D) for mild, moderate or severe chronic heart failure (NYHA II, III or IV), http:\/\/www.msac.gov.au\/internet\/msac\/publishing.nsf\/Content\/1223-public [accessed 09 February 2018]."},{"issue":"3","key":"10.1016\/j.hlc.2018.01.011_bib0140","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cardfail.2010.10.010","article-title":"Nurse-led titration of \u03b2-adrenoreceptor blocking agents in chronic heart failure patients in the community","volume":"17","author":"Driscoll","year":"2011","journal-title":"J Card Fail"},{"issue":"2","key":"10.1016\/j.hlc.2018.01.011_bib0145","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ijcard.2011.02.034","article-title":"Pharmacist directed home medication reviews in patients with chronic heart failure: a randomised clinical trial","volume":"159","author":"Barker","year":"2012","journal-title":"Int J Cardiol"},{"issue":"14","key":"10.1016\/j.hlc.2018.01.011_bib0150","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jacc.2012.06.025","article-title":"Impact of home versus clinic-based management of chronic heart failure the WHICH? (Which Heart Failure Intervention Is Most Cost-Effective & Consumer Friendly in Reducing Hospital Care) multicenter, randomized trial","volume":"60","author":"Stewart","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.hlc.2018.01.011_bib0155","doi-asserted-by":"crossref","first-page":"306","DOI":"10.5694\/j.1326-5377.2010.tb03528.x","article-title":"The effect of evidence-based medication use on long-term survival in patients hospitalised for heart failure in Western Australia","volume":"192","author":"Teng","year":"2010","journal-title":"Med J Aust"},{"issue":"2","key":"10.1016\/j.hlc.2018.01.011_bib0160","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1161\/CIRCHEARTFAILURE.109.879239","article-title":"Heart failure incidence: case fatality, and hospitalization rates in Western Australia between 1990 and 2005","volume":"3","author":"Teng","year":"2010","journal-title":"Circ Heart Fail"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950618300428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950618300428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T18:00:19Z","timestamp":1761415219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950618300428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1443950618300428"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2018.01.011","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Ivabradine in the Treatment of Chronic Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2018.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}